Clarient granted U.K. patent for TLE3 biomarker

[News]

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the United Kingdom Patent Office has granted a U.K. patent on the Company's TLE3 biomarker, a marker which may be used to predict which cancer patients will respond favorably to taxane therapy.

More... (http://www.news-medical.net/news/20100608/Clarient-granted-UK-patent-for-TLE3-biomarker.aspx)